Granisetron as antiemetic therapy in children with cancer

A. W. Craft, L. Price, O. B. Eden, P. Shaw, R. Campbell, D. M. Pierce, R. Murdoch, J. Upward

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


The safety and efficacy of the new 5HT‐3 antagonist granisetron as an antiemetic in children with cancer was evaluated in 40 children at a single dose of 40 μg/kg. No adverse affects attributable to the granisetron were noted. The overall major and complete response rate was 82.5% and this was highest in the younger children. Only 2 patients showed no response. Pharmacokinetic studies showed associations between some pharmacokinetic parameters and age which were no longer apparent after normalisation for body weight. Granisetron is an effective and very well tolerated antiemetic and appears to be an important addition to the supportive care available for children with cancer. © 1995 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
JournalMedical and Pediatric Oncology
Issue number1
StatePublished - Jul 1995
Externally publishedYes


  • antiemetics
  • cancer
  • children
  • emetogenic chemotherapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research


Dive into the research topics of 'Granisetron as antiemetic therapy in children with cancer'. Together they form a unique fingerprint.

Cite this